The American Society of Hematology (ASH) will kick off its 54^th annual meeting next Saturday, December 8. This year’s meeting will run through Tuesday, December 11 and will be held in Atlanta.

Similar to past years, over 20,000 people are expected to attend the meeting to listen to experts from around the world discuss current research regarding the biology, diagnosis, treatment, and progression of various blood diseases, including multiple myeloma.

The ASH meeting, along with the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) meetings, are the three …

During the upcoming annual meeting of the American Society of Hematology (ASH), which will be held December 8 through 11 in Atlanta, results will be presented from clin­i­cal trials involving a number of poten­tial new drugs under devel­op­ment for the treat­ment of multiple myeloma.

In particular, results for newer, lesser known agents that are in the early stages of clin­i­cal devel­op­ment will take center stage. These agents in­clude ARRY-520 (filanesib), BHQ880, circularly permuted TRAIL, daratumumab, dinaciclib, lorvotuzumab mertansine, oprozomib, and tabalumab.

According to the recently …